Evidence map›Paper›PMID 41993926›Full record

ArticleNpj biosensing2026

Circulating tumor cell detection in cancer patients using in-flow deep learning holography.

Kevin Mallery, Nathaniel R Bristow, Nicholas Heller, Yash Travadi, Ali Arafa, Kaylee Kamalanathan, Catalina Galeano-Garces, Mahdi Ahmadi, Grant Schaap, Alexa Hesch and 14 more

Abstract read
In one paragraph

Article in Npj biosensing, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

24 authors.

Kevin Mallery *Astrin Biosciences, St Paul, MN USA.
Nathaniel R Bristow *Astrin Biosciences, St Paul, MN USA.
Nicholas HellerAstrin Biosciences, St Paul, MN USA.
Yash TravadiAstrin Biosciences, St Paul, MN USA.
Ali ArafaDepartment of Pharmacology, Medical School, University of Minnesota - Twin Cities, Minneapolis, MN USA.
Kaylee KamalanathanAstrin Biosciences, St Paul, MN USA.
Catalina Galeano-GarcesAstrin Biosciences, St Paul, MN USA.
Mahdi AhmadiAstrin Biosciences, St Paul, MN USA.
Grant SchaapAstrin Biosciences, St Paul, MN USA.
Alexa HeschAstrin Biosciences, St Paul, MN USA.
Olivia HedeenAstrin Biosciences, St Paul, MN USA.
Zikora IzuoraAstrin Biosciences, St Paul, MN USA.
Joel HapkeAstrin Biosciences, St Paul, MN USA.
Jeffrey MillerAstrin Biosciences, St Paul, MN USA.
Arjun ViswanathanAstrin Biosciences, St Paul, MN USA.
Ivo BabrisAstrin Biosciences, St Paul, MN USA.
Songyi BaeAstrin Biosciences, St Paul, MN USA.
Baisali BhattacharyaDepartment of Pharmacology, Medical School, University of Minnesota - Twin Cities, Minneapolis, MN USA.
Tuan LeAstrin Biosciences, St Paul, MN USA.
Tony ClackoAstrin Biosciences, St Paul, MN USA.
Emmanuel S AntonarakisDepartment of Medicine, Medical School, University of Minnesota - Twin Cities, Minneapolis, MN USA.
Badrinath R KonetyAstrin Biosciences, St Paul, MN USA.
Justin M DrakeAstrin Biosciences, St Paul, MN USA.
Jiarong HongAstrin Biosciences, St Paul, MN USA.

Funding

Women's CancerP30CA077598 · NCI · UNIVERSITY OF MINNESOTA TWIN CITIES · PI Timothy C. Hallstrom · 1998 to 2026
$100.4M
Development of a novel personalized medicine platform using apheretically isolated circulating tumor cells to assess drug responsiveness in prostate cancerR41CA268344 · NCI · ASTRIN BIOSCIENCES, INC. · PI DRAKE, JUSTIN MICHAEL, PARTHASARATHY, JAYANT · 2022 to 2022
$400k
NCI NIH HHS P30 CA077598NCI NIH HHS R41 CA268344
6 · The paper itself

Abstract

Circulating tumor cells (CTCs) are cancer cells found in the bloodstream that serve as biomarkers for early cancer detection, prognostication, and disease monitoring. However, CTC detection remains challenging due to low cell abundance and heterogeneity. Digital holographic microscopy (DHM) offers a promising, label-free method for high-throughput CTC identification by capturing superior morphological information compared to traditional imaging methods, while remaining compatible with in-flow data acquisition. We present a streamlined DHM-based system that integrates microfluidic enrichment with deep learning-driven image analysis, supplemented by immunofluorescent profiling, to improve sensitivity and specificity of CTC enumeration. Specifically, our platform combines inertial microfluidic preprocessing with dual-modality imaging, integrating holography with fluorescence sensing of up to two markers. A deep learning model, trained on a diverse set of healthy blood samples and cancer cell lines, and executed in real-time, provides a morphological confidence on a cell-by-cell basis that may then be combined with immunofluorescence criteria for enumeration. In a pilot study, we demonstrate higher CTC counts in patients with late-stage prostate cancer (

Indexed as

Biological techniquesBiomarkersCancerComputational biology and bioinformaticsOncology

Identifiers

PMID41993926
PMCPMC13079088

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.